People with osteoarthritis have a significantly higher risk for developing cardiovascular disease than those without, and the use of nonsteroidal anti-inflammatory drugs mediates a considerable proportion of this association, researchers report.
Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.
People with osteoarthritis are significantly more likely than those without to have multiple comorbidities, particularly stroke, peptic ulcers, and the metabolic syndrome, show results of a systematic review and meta-analysis of observational data.
Patients with locally advanced non-small-cell lung cancer have a high risk for major adverse cardiac events after radiotherapy that may warrant a reduction in cardiac radiation dose, study findings indicate.
Increased atherosclerotic plaque burden, as estimated by carotid ultrasound, is associated with an increased risk for cardiovascular events in patients with psoriatic disease, Canadian researchers report.
People with diabetes and stable ischemic heart disease are more likely to have long-term survival when they have a greater number of risk factors controlled at prespecified therapeutic goals, research shows.
Among men initiating abiraterone acetate for advanced prostate cancer, the mortality risk may be higher for those with versus without pre-existing cardiovascular disease, suggests a real-world study presented at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA.
A 1-year exercise intervention combining high-intensity interval training with resistance training may improve measures of cardiovascular risk among people with type 2 diabetes, suggests a secondary analysis of the D2FIT trial.
Patients with osteoarthritis or rheumatoid arthritis who take ibuprofen are more likely to experience an increase in systolic blood pressure than those taking celecoxib, results of the PRECISION-ABPM study suggest.
Individuals eligible for statins according to the 2013 American College of Cardiology/American Heart Association guidelines have a significantly increased risk for developing or dying of cancer compared with noneligible individuals, US researchers report.